Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis
Open Access
- 5 May 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (5), 1351
- https://doi.org/10.3390/jcm9051351
Abstract
There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection was performed in 37 patients (72.5%) and 11 of these (29.7%) also received peri-operative platinum-etoposide chemotherapy. Median OS was longer in patients with better performance status (PS) and in those with stage I–III disease at diagnosis compared to stage IV. Among patients who underwent radical tumor resection (N = 37), RFS was longer in patients with better PS and showed a trend towards a longer RFS in those treated with peri-operative chemotherapy than with surgery alone (11 vs. 6 months; p = 0.078). Among 28 patients receiving chemotherapy for metastatic disease, PFS was 5.0 months and there was a trend towards improved PFS in patients receiving carboplatin-etoposide chemotherapy compared to other regimens. A multivariate model unmasked a significant association between carboplatin-etoposide chemotherapy and risk for disease progression or death (HR: 0.39 (95%CI: 0.16–0.96) p = 0.040). Performance status might be associated with improved RFS in radically operated patients, while type of chemotherapy might affect PFS in patients receiving chemotherapy for metastatic BNEC.This publication has 17 references indexed in Scilit:
- Staging of bladder cancerHistopathology, 2018
- The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary TractAnticancer Research, 2018
- Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct PathogenesisClinical Cancer Research, 2018
- Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of NeoplasmsEndocrine Pathology, 2016
- Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 PatientsInternational Journal of Radiation Oncology*Biology*Physics, 2015
- Long‐term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladderInternational Journal of Urology, 2015
- Distinct genetic alterations in small cell carcinoma from different anatomic sitesExperimental Hematology & Oncology, 2015
- Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial CancerJournal of Clinical Oncology, 2009
- Small cell carcinoma of the urinary bladderCancer, 2005
- Small cell carcinoma of the urinary bladderCancer, 2004